Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608842 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study for the Treatment of Superficial Lipomas
A Phase 2 study of Lipoma, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT00608842 is a Phase 2 study of Lipoma that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 62 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT00608842, a Phase 2 study of Lipoma, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research is to compare the safety and effectiveness of 3 different concentrations of deoxycholic acid for injection against a placebo in the treatment of superficial lipomas.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deoxycholic Acid Injection
Study Locations (7)
Alabama
- Gary D. Monheit, M.D. - Birmingham
California
- Stacy R. Smith - San Diego
Michigan
- Steven Grekin, D.O. - Warren
Nebraska
- Joel Schlessinger, M.D. - Omaha
New Jersey
- David J. Goldberg, M.D. - Westwood
New York
- Neil S. Sadick, M.D. - New York
Tennessee
- Michael H. Gold, M.D. - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608842
The ClinicalTrials.gov registry entry for NCT00608842 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00608842 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT00608842 about?
NCT00608842 is a clinical study titled "Phase 2 Study for the Treatment of Superficial Lipomas". The purpose of this research is to compare the safety and effectiveness of 3 different concentrations of deoxycholic acid for injection against a placebo in the treatment of superficial lipomas.
What is the current status of trial NCT00608842?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2007-11. Estimated completion is 2010-01.
What conditions does trial NCT00608842 study?
This clinical trial studies the following conditions: Lipoma.
What interventions are being tested in trial NCT00608842?
The interventions under investigation include: Placebo (DRUG), Deoxycholic Acid Injection (DRUG).
Who is sponsoring clinical trial NCT00608842?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00608842 being conducted?
This trial has 7 study locations across Alabama, California, Michigan, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.